Abstract

Abstract Purpose The aim of this multicenter retrospective study was to evaluate the impact of statin use on clinical outcomes in patients with unresectable pancreatic cancer (PC) receiving gemcitabine plus nab-paclitaxel (GnP) in a large Japanese cohort. Methods We retrospectively reviewed the medical records including data on the use of concomitant medications in patients with unresectable PC receiving GnP between January 2015 and January 2019 at 10 hospitals. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were evaluated. Results A total of 1682 patients were included in the analysis; of which 322 patients (19%) received statins and 1360 (81%) did not receive statin. The median PFS and OS were 7.5 vs. 7.3 months (p = 0.87) and 15.1 vs. 14.4 months (p = 0.48) in cases with and without statin use. The use of statin was not associated with PFS (hazard ratio [HR] 1.01, 95% confidence interval [CI], 0.85-1.18, p = 0.93) or OS (HR 1.05, 95%CI, 0.91-1.21, p = 0.47) in the multivariable analyses. PFS and OS did not significantly differ by liposolubility of statins, either. Conclusions Stain use was not associated with PFS or OS in patients with unresectable PC receiving GnP.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.